Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models-Reference-Cited by-同舟云学术

Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models

Published:2019-09 Issue:9 Volume:27 Page:1547-1557
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Kim Youngsoo,Jo Minji,Schmidt Joanna,Luo Xiaolin,Prakash Thazha P.,Zhou Tianyuan,Klein Stephanie,Xiao Xiaokun,Post Noah,Yin Zhengfeng,MacLeod A. Robert

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference39 articles.

1. Hepatocellular carcinoma;Forner;Lancet,2012

2. Sorafenib in advanced hepatocellular carcinoma;Llovet;N. Engl. J. Med.,2008

3. RNA-Targeted Therapeutics;Crooke;Cell Metab.,2018

4. ISS-N1 makes the First FDA-approved Drug for Spinal Muscular Atrophy;Ottesen;Transl. Neurosci.,2017

5. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis;Benson;N. Engl. J. Med.,2018

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RNase H-sensitive multifunctional ASO-based constructs as promising tools for the treatment of multifactorial complex pathologies;Bioorganic Chemistry;2024-09

2. Targeting pediatric solid tumors in the new era of RNA therapeutics;Critical Reviews in Oncology/Hematology;2024-08

3. Single cell glycan-linkages profiling for hepatocellular carcinoma early diagnosis using lanthanide encoded bacteriophage MS2 based ICP-MS;Talanta;2024-07

4. Treatment of transthyretin cardiac amyloidosis;Current Opinion in Cardiology;2024-04-19

5. Innovative Genoceuticals in Human Gene Therapy Solutions: Challenges and Safe Clinical Trials of Orphan Gene Therapy Products;Current Gene Therapy;2024-02